SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy

SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-M™ Autologous SIRPαlow Activated Macrophage Immunotherapy

See more here

Comments are closed.